Circadian Therapeutics develops products that target serious diseases associated with circadian rhythm disruption.

Circadian Therapeutics develops products that target serious diseases associated with circadian rhythm disruption.

Circadian Therapeutics

Circadian Therapeutics was founded in September 2016 as a spin-out from Oxford University with the aim to deliver benefit and value for all its stakeholders; patients, healthcare providers and investors. The world-leading science generated by its academic founders is the foundation for the development of therapeutic products based on the understanding of the molecular control of circadian rhythms. With an experienced leadership team and a track-record of building operational capabilities and delivering shareholder value, the Company will develop therapeutics targeting serious diseases associated with circadian rhythm disruption.

Read more

Circadian Rhythms

Circadian rhythms are essential for synchronising the daily cycle of all organisms keeping internal body functions aligned with the dawn dusk cycle. In humans, it governs a host of critical physiological and behavioural processes including body temperature, cardiovascular function, hormone production and sleep. However, if these rhythms are disrupted by factors such as genetic mutation, ageing, illness, travel or shift-work, serious detrimental consequences to health and well-being may arise.

Read more

Portfolio

The Company is developing a balanced portfolio of products to address a broad range of disorders associated with circadian rhythm disruption. All products under development are based on the pharmacological modulation of the biological clock to treat the cause of the disease rather than merely addressing the symptoms.

Read more